Response to Comments: Prolaris Prostate Cancer Genomic Assay

Policy A54616 documents that CGS Administrators received no comments on DL36002 Prolaris Prostate Cancer Genomic Assay during the open comment period (06/17/2015–08/03/2015). No coverage criteria, exclusions, documentation requirements, or frequency limits were changed or recorded as a result of the comment period.